MedTrace Logo

Futibatinib in Combination With (Chemo)Immunotherapy in Colorectal Cancer and Other Solid Tumor Entities

NCT06722183 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2025-12-24

No results posted yet for this study

Summary

The FUTURE trial is a prospective, multicentre, exploratory, open-label phase II platform trial. Its goal is to evaluate the efficacy, feasibility and safety of futibatinib combined with immunotherapeutic, targeted or chemotherapeutic agents in colorectal and other solid tumors and to additionally identify biomarkers that correlate with clinical outcome.

Conditions

Interventions

DRUG

Futibatinib orally administered

Futibatinib will be administered 20mg orally, once daily, continously

DRUG

Tislelizumab (i.v. 200mg)

Tislelizumab (i.v. 200mg) will be administered on day 1 and day 22 of a 6-week cycle

Sponsors & Collaborators

  • Universitätsmedizin Mainz, I. Medizinische Klinik, Forschungslabor Prof. Möhler

    collaborator UNKNOWN

  • Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

    lead OTHER

Principal Investigators

  • Salah Al-Batran, Prof. Dr. · Institut für Klinische Krebsforschung IKF GmbH

  • Thorsten O. Götze, Prof. Dr. · Institute of Clinical Cancer Research, UCT - University Cancer Center Frankfurt Krankenhaus Nordwest

  • Markus Möhler, Prof. Dr. · Johannes Gutenberg-University Clinic Mainz

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-16
Primary Completion
2028-03-31
Completion
2028-03-31
FDA Drug
Yes

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06722183 on ClinicalTrials.gov